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Abstract Although the cyclooxygenase-2 (COX-2) pathway of
the arachidonic acid cascade has been suggested to play an
important role in colon carcinogenesis, there is little information
concerning the identity of phospholipase A2 (PLA2) involved in
the arachidonic acid release in colon tumors. Here, we compared
the potencies of three types of secretory PLA2s (group IB, IIA
and X sPLA2s) for the arachidonic acid release from cultured
human colon adenocarcinoma cells, and found that group X
sPLA2 has the most powerful potency in the release of
arachidonic acid leading to COX-2-dependent prostaglandin E2
(PGE2) formation. Furthermore, immunohistological analysis
revealed the elevated expression of group X sPLA2 in human
colon adenocarcinoma neoplastic cells in concert with augmented
expression of COX-2. These findings suggest a critical role of
group X sPLA2 in the PGE2 biosynthesis during colon
tumorigenesis. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
A growing body of evidence has shown that non-steroidal
anti-in£ammatory drugs (NSAIDs) can suppress colorectal
tumorigenesis in both humans and rodents [1]. The molecular
basis for their chemopreventive e¡ects has been attributed at
least, in part, to the inhibition of cyclooxygenase-2 (COX-2),
since COX-2 expression is elevated in human colorectal tu-
mors [2,3]. In addition, inactivation of the COX-2 gene is
associated with decreased intestinal tumorigenesis in rodent
models of familial adenomatous polyposis (FAP) [4]. COX-2
catalyzes the conversion of arachidonic acid to prostaglandin
H2 (PGH2) leading to the production of various bioactive
PGs [5]. Among these eicosanoids, PGE2 is produced in large
amounts by colon tumors [6], and supports tumor growth by
inducing angiogenesis [7], modulating tumor cell apoptosis [8],
and suppressing immune surveillance [9]. A potential role of
PGE2 in colon tumorigenesis has also been demonstrated by a
recent study of mice de¢cient in PGE2 receptor subtype EP1,
which showed reduced development of aberrant crypt foci in
treatment with a colon carcinogen [10].
The release of arachidonic acid from cell membrane phos-
pholipids is mainly mediated via the action of phospholipase
A2 (PLA2) [11]. To date, numerous types of PLA2s have been
identi¢ed and classi¢ed into di¡erent families according to
their biochemical features [11]. Among them, secretory PLA2s
(sPLA2s) are the secreted enzymes that possess several char-
acteristic features, including a low molecular mass (13^18
kDa) and an absolute catalytic requirement for millimolar
concentrations of Ca2 [11]. Based on the primary structures,
human sPLA2s are now classi¢ed into seven di¡erent groups
(IB, IIA, IID, IIE, III, V and X) [11^14]. Previous studies
have shown that the sPLA2-IIA gene represents the Mom1
locus, which is known as a genetic modi¢er of tumor resis-
tance in the multiple intestinal neoplasia (Min) mouse, a mur-
ine model for FAP [15]. However, its functional signi¢cance in
human colorectal carcinogenesis has not been elucidated, as
there is no modifying e¡ect of sPLA2-IIA polymorphisms on
the severity of polyposis in FAP patients [16]. Another type of
PLA2 family, cytosolic PLA2 (cPLA2), has been identi¢ed as
playing pivotal roles in the release of arachidonic acid and the
lipid mediator productions in various in£ammatory disease
models [17,18]. Recent studies have shown that the introduc-
tion of a cPLA2 gene mutation into the Apcv716 knockout
mouse, a model for human FAP, results in the reduction of
the size of the small intestinal polyps with no alternation in
the colonic polyps formation [19]. These ¢ndings suggest that
cPLA2 plays a role in the expansion of polyps in the small
intestine, but other types of PLA2s are involved in the polyps
formation in the colon.
Recently, we found that group X sPLA2 (sPLA2-X) has the
strongest potency for releasing arachidonic acid from phos-
phatidylcholine among the sPLA2 family enzymes and elicits a
marked release of arachidonic acid leading to eicosanoid for-
mation in various in£ammatory cells [20^22]. These observa-
tions prompted us to examine its potential role in PGE2 bio-
synthesis during colon tumorigenesis. Here, we found a strong
potency of sPLA2-X in the arachidonic acid release linked to
the COX-2-dependent PGE2 production in cultured human
colon tumor cells, and also presented the evidence for a
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marked expression of sPLA2-X in human colon adenocarci-
noma tumors by immunohistochemical analysis.
2. Materials and methods
2.1. Materials
Puri¢ed recombinant human group IB sPLA2 (sPLA2-IB) and
sPLA2-X were prepared as described previously [20]. Recombinant
human sPLA2-IIA and rabbit anti-cPLA2 antibody were generous
gifts from Dr. Ruth Kramer (Eli Lilly, Indianapolis, IN, USA). Rab-
bit anti-human sPLA2-X antibody was prepared in our laboratories
[20], and antibodies against sPLA2-IB, sPLA2-IIA, COX-1 and COX-
2 were purchased from Cayman Chemicals. Bovine serum albumin
(BSA), indomethacin and A23187 were obtained from Sigma. Indox-
am was synthesized at Shionogi Research Laboratories [23].
AACOCF3 was obtained from Cayman Chemicals.
2.2. Assay for fatty acid release and PGE2 production in sPLA2-treated
human adenocarcinoma cell lines
Human colon carcinoma cell lines (HT-29, HCT-15, HCT-116 and
Colo320DM; obtained from ATCC) were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS). For the analysis of fatty
acid releases, the tumor cells were harvested from the culture dishes
and suspended in Hanks’ bu¡ered saline (pH 7.6) containing 0.1%
BSA at a density of 12.5U106 cells/ml. Aliquots of cell suspension
(0.4 ml) were preincubated for 10 min at 37‡C, and then stimulated
with sPLA2s or 10 WM A23187 in a ¢nal volume of 0.5 ml. The
reaction was stopped by the addition of 2 ml Dole’s reagent, and
the released fatty acids were extracted, labeled with 9-anthryldiazo-
methane (Funakoshi Co.), and analyzed by reverse-phase high per-
formance liquid chromatography on a LiChroCART 125-4 Super-
spher 100 RP-18 column (Merck), as described previously [20]. For
the PGE2 production assay, colon carcinoma cells were seeded in
24-well plates at a density of 2.5U105 cells/well. After the incubation
for 24 h, the cells were washed three times with phosphate-bu¡ered
saline (PBS) and incubated with or without recombinant human
TNF-K (30 ng/ml; RpD Systems Inc.) in 10% FBS/DMEM for 18 h
at 37‡C. After washing, the cells were preincubated either with or
without several inhibitors in Hanks’ bu¡ered saline (pH 7.6) contain-
ing 0.1% BSA for 10 min at 37‡C, and then stimulated with sPLA2s or
10 WM A23187 in a ¢nal volume of 0.5 ml. After the incubation for
37‡C, the culture supernatant was collected following centrifugation,
and the PGE2 content was quanti¢ed with an enzyme-immunoassay
kit (Cayman Chemicals Co.).
2.3. Western blot analysis of COX-1 and COX-2 expression
Human colon carcinoma cells were cultured in 24-well plates and
treated with or without TNF-K as described above. After washing
with PBS, the cells were solubilized with Laemmli sample bu¡er con-
taining 5% 2-mercaptoethanol. Equal volumes of the samples were
then separated by sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis using a 4^20% gradient gel (Daiichi Chemicals Co., Ltd.).
After proteins were transferred to an Immobilon-P membrane (Milli-
pore Co., Ltd.), Western blot analysis with anti-COX-1 or anti-COX-
2 antibody (0.6 Wg/ml) was performed as described in the previous
paper [20] and the resultant signals were acquired with an image
analyzer (Flour-S MultiImager, Bio-Rad).
2.4. Immunohistochemistry
Preparations of human normal colon tissues (four males; age 40^53
years) and colon adenocarcinoma tissues (¢ve males and one female;
ages 45^73 years) were purchased from Biochain Inc. (San Leandro,
CA, USA). The tissue slides were dewaxed, incubated in methanol
containing 0.3% H2O2 for 30 min and then treated with 5% normal
rabbit serum for 20 min. The slides were incubated with anti-sPLA2-X
(6 Wg/ml), anti-sPLA2-IB (5 Wg/ml), anti-sPLA2-IIA (7 Wg/ml), anti-
cPLA2 (1/1000 dilution), or anti-COX-2 antibodies (0.25 Wg/ml) in
PBS containing 0.1% BSA for 1 h at room temperature. After washing
with PBS, they were incubated with biotin-conjugated goat anti-rabbit
antibody for 30 min followed by treatment with horseradish peroxi-
dase avidin^biotin complex reagent (Vector Laboratories). After
washing, the peroxidase activity was visualized by 10 min incubation
in 50 mM Tris^HCl (pH 7.6) containing 200 mg/ml of diaminobenzi-
dine and 0.006% H2O2. The nuclei were counterstained with 0.4%
hematoxylin and the preparations were mounted in Entellan new me-
dium. Positive signals were detected as diaminobenzidine deposits of
dark-brownish color. Neutralization of sPLA2-X signals was per-
formed by incubating anti-sPLA2-X antibody with sPLA2-X protein
(60 Wg/ml) for 2 h before addition to the slides. The availability of the
Fig. 1. Release of arachidonic acid from sPLA2-X-stimulated human
colon adenocarcinoma cells. A: The amount of arachidonic acid re-
leased from HT-29, Colo320DM, HCT-15 and HCT-116 cells by
the actions of 500 nM sPLA2-X, 500 nM sPLA2-IIA and 10 WM
A23187 for 30 min. B: Dose-dependent release of arachidonic acid
from HT-29 cells by the actions of sPLA2-X, sPLA2-IB and sPLA2-
IIA for 30 min. C: Inhibitory potencies of sPLA2 inhibitor indox-
am, cPLA2 inhibitor AACOCF3, and COX inhibitors, indomethacin
(IM) and NS-398 at 10 WM, against the arachidonic acid release
from HT-29 cells treated with 100 nM sPLA2-X for 30 min. The re-
sults are expressed as the percentage of arachidonic acid released by
sPLA2-X in the absence of these agents. Each point represents the
mean S.D. of triplicate measurements. The data are representative
of three experiments.
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antibodies for immunohistochemical analysis was con¢rmed with each
positive tissue preparation.
3. Results
3.1. Potency of sPLA2-X in arachidonic acid release in cultured
human colon tumor cells
We ¢rst examined the potencies of sPLA2-IIA, sPLA2-X
and cPLA2 activator A23187 in releasing arachidonic acid
from four di¡erent types of human colon carcinoma cell lines.
Each reaction reached a steady state level within 30 min, and
Fig. 1A summarizes the amount of arachidonic acid released
within 30 min. sPLA2-X was found to elicit more potent re-
lease than sPLA2-IIA and A23187 in four di¡erent cell types.
Among the carcinoma cells examined, the strongest releases
were observed in HT-29 cells, in which sPLA2-X induced the
release of other unsaturated fatty acids (oleic acid: 1060
pmol/ml and palmitoleic acid: 700 pmol/ml) more e⁄ciently
than arachidonic acid (230 pmol/ml). Fig. 1B shows the dose-
dependence of three types of sPLA2s in the arachidonic acid
release in HT-29 cells. Signi¢cant release was observed in
the sPLA2-X-treated cells at 5 nM, whereas sPLA2-IIA could
not induce a signi¢cant release even at 500 nM. sPLA2-IB also
induced arachidonic acid release at more than 50 nM with
lower potency than sPLA2-X. To investigate the mecha-
nisms underlying the sPLA2-X-induced release reactions, the
e¡ects of several inhibitors (10 WM) were examined. In con-
trast to e⁄cient suppression by a speci¢c sPLA2 inhibitor,
indoxam [23], a known cPLA2 inhibitor, AACOCF3, and
two COX inhibitors, indomethacin and NS-398, did not sup-
press the responses (Fig. 1C), demonstrating that cPLA2 is
not involved in the sPLA2-X-induced fatty acid release reac-
tions.
3.2. Potency of sPLA2-X in COX-2-dependent PGE2 formation
in cultured colon tumor cells
Next, the potency of sPLA2-X in PGE2 production was
examined in HT-29 cells, in which COX-1 was constitutively
expressed and COX-2 was strongly induced by treatment with
several pro-in£ammatory cytokines such as TNF-K [24]. In
the resting cells, COX-2 protein could not be detected and
sPLA2-X (500 nM) did not evoke signi¢cant PGE2 production
for up to 4 h (Fig. 2A). After the induction of COX-2 by
pretreatment with TNF-K, sPLA2-X induced a time-depen-
dent increase of PGE2 formation. This reaction was slower
than that induced by A23187, and the PGE2 level at 6 h after
sPLA2-X stimulation was calculated to be 1.6 nM, which was
about 2.5-fold higher than the maximum level induced by 10
WM A23187 (at 30 min incubation). In contrast, there was no
detectable production in sPLA2-X-treated HCT-15 and HCT-
116 cells (data not shown), where COX-1 was constitutively
expressed and COX-2 could not be induced even after treat-
ment with pro-in£ammatory cytokines [25]. These ¢ndings
suggest that the sPLA2-X-induced PGE2 formation is com-
pletely dependent on COX-2 expression in human colon tu-
mor cells. As shown in Fig. 2B, signi¢cant PGE2 production
was observed at 10 nM sPLA2-X in TNF-K-pretreated HT-29
cells, whereas sPLA2-IB evoked much weaker responses even
at 500 nM and sPLA2-IIA did not provoke any productions.
As shown in Fig. 2C, indoxam suppressed the sPLA2-X-
stimulated PGE2 production in a dose-dependent manner.
In addition, indomethacin and NS-398 blocked the response
Fig. 2. COX-2-dependent PGE2 production in sPLA2-X-stimulated
HT-29 cells. A: Time-dependent PGE2 formation by sPLA2-X in
TNF-K-pretreated HT-29 cells. HT-29 cells were pretreated with
(circles) or without (triangles) 30 ng/ml TNF-K for 18 h. After
washing, the cells were stimulated with 500 nM sPLA2-X for the in-
dicated times. The expression of COX-2, as assessed by Western
blotting, is shown in the inset. B: Dose-dependent production of
PGE2 by sPLA2s in TNF-K-pretreated HT-29 cells. After pretreat-
ment with TNF-K, HT-29 cells were incubated with various concen-
trations of sPLA2-X, sPLA2-IB and sPLA2-IIA for 3 h. C: Inhibi-
tion of sPLA2-X-induced PGE2 production. After pretreatment with
TNF-K, HT-29 cells were preincubated with indoxam, NS-398 and
indomethacin (IM), and then stimulated with 100 nM sPLA2-X for
3 h. The results are expressed as the percentage of PGE2 produced
by sPLA2-X in the absence of these agents. Each point represents
the mean S.D. of triplicate measurements. The data are representa-
tive of three experiments.
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with IC50 values of about 2 nM, demonstrating complete de-
pendency of PGE2 biosynthesis on COX-2 activity.
3.3. Immunohistochemical analysis of sPLA2-X expression in
human colon adenocarcinoma tumor tissues
We have recently developed a polyclonal antibody that spe-
ci¢cally recognizes sPLA2-X among the human sPLA2 species
[20]. Immunohistological analysis of normal human colon tis-
sues revealed little, if any, expression of sPLA2-X (Fig. 3A).
In contrast, marked expression of sPLA2-X was detected in
human well-di¡erentiated adenocarcinoma tissues, especially
in the neoplastic epithelium and in some in£ammatory cells
present within the stroma (Fig. 3B). The signal was speci¢c,
since preincubation of the antibody with an excess amount of
sPLA2-X protein resulted in its complete abolishment (Fig.
3C). In addition, there was no signal when non-immunized
control IgG was used (data not shown). Enhanced expression
of sPLA2-X was detected in the well-di¡erentiated carcinomas
of six di¡erent patients, and their expression levels were sim-
ilar to those detected in the moderately and poorly di¡eren-
tiated cases (data not shown). We then examined the ex-
pression pro¢les of other PLA2 species with their speci¢c
antibodies, and found no signals in normal colon tissues
(data not shown). In colon adenocarcinoma tissues, there
was no detectable signal for sPLA2-IB and sPLA2-IIA (Fig.
3D,E), whereas slight but signi¢cant signals for cPLA2 were
detected in colon cancer cells and in some in£ammatory cells
of colonic stroma (Fig. 3F). The expression of COX-2 was
strongly detected within colon neoplastic cells and stroma
cells (Fig. 3G) in contrast to no signi¢cant signal in normal
tissues. These ¢ndings demonstrate that the expressions of
sPLA2-X and COX-2 are greatly enhanced in colorectal tu-
mor cells.
4. Discussion
The present study demonstrates that sPLA2-X induces a
marked release of arachidonic acid leading to COX-2-depen-
dent PGE2 formation in cultured human colon adenocarcino-
ma cells. In human colorectal cancer tissues, the expression of
sPLA2-X was greatly up-regulated and correlated well with an
elevated expression of COX-2, suggesting a pivotal role of
sPLA2-X in the COX-2-dependent PGE2 biosynthesis during
colon tumorigenesis. The expression of cPLA2 could also be
Fig. 3. Immunostaining for sPLA2s, cPLA2 and COX-2 in normal colon and colorectal adenocarcinoma tissues. Human normal colon (A) and
well-di¡erentiated colorectal adenocarcinoma tissues (B) were immunostained with anti-sPLA2-X antibody (6 Wg/ml). Control staining with anti-
sPLA2-X antibody absorbed with human sPLA2-X protein (60 Wg/ml) (C) was completely negative in colorectal adenocarcinoma tissues. Hu-
man colorectal adenocarcinoma tissues were also immunostained with anti-sPLA2-IB (D), anti-sPLA2-IIA (E), anti-cPLA2 (F) and anti-COX-2
antibodies (G). The positive signals were detected as diaminobenzidine deposits of dark-brownish color, and the nuclei were counterstained
with hematoxylin. Bar indicates 100 microns.
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detected in colon adenocarcinoma tissues (Fig. 3). Compared
with cPLA2 activator A23187, sPLA2-X could elicit more po-
tent release of arachidonic acid in various colon tumor cells
(Fig. 1A). In addition, the sPLA2-X-induced PGE2 formation
was much slower in contrast to a prompt response by A23187
in COX-2-expressing HT-29 cells (Fig. 2A). These ¢ndings
suggest that sPLA2-X plays a role in the sustained PGE2
production in colon tumor cells. The enzymatic activity of
sPLA2-X is known to be regulated by the conversion of its
pro-form to the mature enzyme via proteolytic removal of the
propeptide [20,21]. Since several proteases such as trypsin are
expressed at high levels in colon cancer tissues and colon
tumor cells actively secrete trypsinogens and several proteases
[26], the conversion rate from pro-form to active sPLA2-X
could be accelerated during the development of colon tumors.
Because recent gene deletion studies have shown that cPLA2
plays a role in the expansion of polyps in the small intestine,
but not in the initiation process neither the polyps formation
in the colon [19], the functional role of sPLA2-X in colon
tumorigenesis deserves attention in the future. Further studies
such as the analysis of the promoter regions of sPLA2-X genes
may also o¡er more information regarding the regulatory
mechanisms of its expression during colon carcinogenesis.
Recent studies have shown the presence of COX-2-inde-
pendent mechanisms underlying the NSAIDs-induced apopto-
sis of colon tumor cells, including the suppression of per-
oxisome proliferator-activated receptor N (PPARN) gene
expression [27]. In the present study, sPLA2-X elicited potent
releases of various types of unsaturated fatty acids from hu-
man carcinoma cells, and these fatty acids and eicosanoids
can act as endogenous ligands and modi¢ers of PPAR activity
[27,28]. In this context, sPLA2-X might modify the spectrum
of PPARN ligands leading to the alteration of PPARN activity
in colon tumors. Furthermore, potent fatty acid releases from
membrane phospholipids could cause enhanced production of
a variety of lysophospholipids, which are known to induce
diverse biological responses in non-speci¢c or Edg-receptor-
mediated fashions, including tumor cell proliferation [29]. In
contrast to selective inhibition of COX-2 inhibitor for PG
production, the sPLA2 inhibitor can suppress the formation
of various types of sPLA2-X-induced lipid mediators, includ-
ing unsaturated fatty acids, eicosanoids, and lysophospholip-
ids. Further elucidation of the biological functions of these
lipid mediators in colon tumorigenesis should give us more
information concerning the therapeutic potential of sPLA2-X
inhibitors for colon cancer.
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